<DOC>
	<DOCNO>NCT00003013</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining surgery chemotherapy may kill tumor cell . It yet know treatment regimen effective breast cancer . PURPOSE : Randomized phase III trial study effectiveness chemotherapy plus surgery treat woman breast cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Surgery Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate whether 8 course primary chemotherapy adequate surgery breast tumor locoregional radiotherapy plus tamoxifen 5 year improve disease-free overall survival woman operable breast carcinoma tumor diagnosis great 2 cm diameter . - Assess whether , postoperative arm , addition paclitaxel doxorubicin CMF ( cyclophosphamide , methotrexate , fluorouracil ) improve disease-free overall survival patient . - Define incidence pathologic complete response ( CR ) induce 8 course primary chemotherapy contain paclitaxel . - Assess whether pathologic CR independent predictor disease-free overall survival . - Evaluate effect primary chemotherapy rate quality breast conserve surgery . OUTLINE : This randomize , multicenter study . Patients stratify center , tumor diameter mammography , nuclear histological grade , estrogen/progesterone receptor status . Patients randomize one three treatment arm . - Arm I : Patients receive doxorubicin IV 15 minute every 3 week 4 course . Beginning 21 day last administration doxorubicin , patient receive cyclophosphamide IV , methotrexate IV , fluorouracil IV day 1 8 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Arms II III : Patients receive doxorubicin IV 15 minute paclitaxel IV 3 hour every 3 week 4 course . Beginning 21 day last administration doxorubicin paclitaxel , patient receive cyclophosphamide IV , methotrexate IV , fluorouracil IV day 1 8 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . All patient either mastectomy breast conserving surgery ; patient unclear surgical margin may second surgery ( re-resection total mastectomy ) radiotherapy . Lymph node axillary dissection perform least second level . For patient 2 adjuvant arm ( arm I II ) , adjuvant chemotherapy start day 21 surgery . For patient primary chemotherapy arm ( arm III ) , surgery perform day 28 last course chemotherapy resolution possible hematological infective complication . At end combine surgery plus chemotherapy approach ( i.e. , last course CMF ( arm I II ) surgery ( arm III ) ) , patient enrol June 30 , 2000 estrogen progesterone receptor positive disease receive oral tamoxifen daily 5 year . All patient breast conserve surgery receive postoperative irradiation within 4 week complete chemotherapy surgery ( i.e. , within 4 week last dose adjuvant chemotherapy ( arm I II ) surgery ( arm III ) ) . All patient mastectomy pT4 disease must receive irradiation chest wall . Patients follow 6 , 12 , 18 , 24 month , annually thereafter . PROJECTED ACCRUAL : A total 450 patient per arm accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Unilateral carcinoma breast previously treat standard therapy Tumor great 2 cm maximum diameter assess mammography , except : No locally advanced disease , i.e. , tumor direct extension chest wall skin No metastatic disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 70 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 80100 % Hematopoietic : Granulocyte count least 2,000/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin within upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN AST great 1.5 time ULN No chronic active hepatitis Renal : Creatinine within ULN Cardiovascular : No prior atrial ventricular arrhythmia No history congestive heart failure No myocardial infarction within past 6 month No uncontrolled hypertension Neurologic : No preexist motor sensory neuropathy great grade 1 Other : Not pregnant nursing Fertile patient must use effective contraception No active infection No history second malignancy except adequately treat basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior endocrine therapy Radiotherapy : No prior radiotherapy Surgery : No prior surgery No prior surgical biopsy breast nodule</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>